Reshma Kewalramani

Reshma Kewalramani, who brings her experience as a licensed doctor to her leadership, took the helm as CEO of Vertex Pharmaceuticals in 2020, having previously served as the biopharma company’s chief medical officer. Vertex, valued at over $110 billion, has become a major player in drug discovery. This year, the company gained FDA approval for a new opioid-free pain drug, Journavx, the first in two decades. Vertex is best known for developing multiple novel drug combinations to treat cystic fibrosis, which affects 100,000 people globally.